Rapamune (sirolimus) 1 mg, 100 tablets, Pfizer, Italy, original Rapamune (sirolimus) is used to help prevent organ transplant rejection. Medicine delivery from Europe with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.

Rapamune is for oral use only.

It is not recommended to disrupt the integrity of the tablets before swallowing them due to the fact that the bioavailability of the drug after crushing, chewing or breaking the tablets has not been studied.

Patients who are unable to take Rapamune in tablet form should receive it as an oral solution.

Rapamune should be taken continuously, either at the same time as meals or between meals.

Therapy should be carried out in a specially equipped place and under the supervision of a transplantologist.

It is recommended to take Rapamune 4 hours after taking cyclosporine microemulsion.

Adults

Initial therapy (within 2-3 months after transplant): In the usual dosing regimen, as soon as possible after transplant, a single loading dose of 6 mg of Rapamune is administered orally, followed by a dose of 2 mg once daily. Subsequently, the dose of Rapamune is selected individually so that minimum blood concentrations range from 4 to 12 ng/ml (chromatographic method). Treatment with Rapamune is continued while simultaneously gradually reducing the dose of glucocorticosteroids and cyclosporine microemulsion.

During the first 2-3 months after transplantation, it is recommended to maintain minimum concentrations of cyclosporine within the range of 150-400 ng/ml (immune method for determining concentrations).

Maintenance therapy: 4-8 weeks after starting treatment with cyclosporine, its dose should be gradually reduced until the drug is completely discontinued, and the dose of Rapamune should be adjusted so that minimum blood concentrations range from 12 to 20 ng/ml (chromatographic method). Rapamune should be taken along with corticosteroids. For patients in whom cyclosporine withdrawal was unsuccessful or impossible, the duration of combined therapy with cyclosporine and Rapamune should not be more than 3 months. In clinically appropriate situations, these patients should discontinue Rapamune and initiate an alternative immunosuppressive regimen.